108 related articles for article (PubMed ID: 1405703)
21. p75c-myb expression in leukemia-lymphoma cells correlated with proliferation and differentiation.
Ohnishi H; Kamano H; Tanaka T; Okabe A; Irino S
Leuk Res; 1990; 14(5):423-32. PubMed ID: 2189045
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
23. MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
Chen P; Redd L; Schmidt Y; Koduru P; Fuda F; Montgomery-Goecker C; Kumar K; Xu-Monette Z; Young K; Collins R; Chen W
Leuk Res; 2021 Jul; 106():106584. PubMed ID: 33933715
[TBL] [Abstract][Full Text] [Related]
24. Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia.
Pelicci PG; Lanfrancone L; Brathwaite MD; Wolman SR; Dalla-Favera R
Science; 1984 Jun; 224(4653):1117-21. PubMed ID: 6585957
[TBL] [Abstract][Full Text] [Related]
25. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
[TBL] [Abstract][Full Text] [Related]
26. Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.
Preisler HD; Raza A; Larson R; LeBeau M; Browman G; Goldberg J; Grunwald H; Volger R; Verkh L; Singh P
Blood; 1989 Jan; 73(1):255-62. PubMed ID: 2910363
[TBL] [Abstract][Full Text] [Related]
27. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of "short-term" effects of chemotherapy on MYC and histone H3 mRNA levels in acute leukemia patients.
Venturelli D; Lange B; Narni F; Selleri L; Mariano MT; Torelli U; Gewirtz AM; Calabretta B
Proc Natl Acad Sci U S A; 1988 May; 85(10):3590-4. PubMed ID: 3285345
[TBL] [Abstract][Full Text] [Related]
29. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines.
Anfossi G; Gewirtz AM; Calabretta B
Proc Natl Acad Sci U S A; 1989 May; 86(9):3379-83. PubMed ID: 2541445
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of nuclear proto-oncogenes in T cells triggered with mitogenic and nonmitogenic T3 and T11 activation signals.
Shipp MA; Reinherz EL
J Immunol; 1987 Oct; 139(7):2143-8. PubMed ID: 2821108
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
[TBL] [Abstract][Full Text] [Related]
32. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
33. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
Calabretta B; Sims RB; Valtieri M; Caracciolo D; Szczylik C; Venturelli D; Ratajczak M; Beran M; Gewirtz AM
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2351-5. PubMed ID: 2006173
[TBL] [Abstract][Full Text] [Related]
34. [Altered expression of protooncogenes during clinical course in an AML case transformed from MDS].
Fujikawa T; Horiguchi J; Iizuka K; Nemoto T; Iwase S; Yamamura S; Inaba S; Yamazaki Y; Sano S; Yamada H
Rinsho Ketsueki; 1991 Sep; 32(9):986-90. PubMed ID: 1942545
[TBL] [Abstract][Full Text] [Related]
35. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
36. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
[TBL] [Abstract][Full Text] [Related]
37. The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes.
Preisler HD; Raza A; Larson R; Goldberg J; Tricot G; Browman G; Bennett J
Leuk Lymphoma; 1994 Jul; 14(3-4):273-8. PubMed ID: 7950916
[TBL] [Abstract][Full Text] [Related]
38. Expression of the protooncogenes c-myc, c-fos, and c-fms in acute myelocytic leukemia at diagnosis and in remission.
Preisler HD; Kinniburgh AJ; Wei-Dong G; Khan S
Cancer Res; 1987 Feb; 47(3):874-80. PubMed ID: 2433029
[TBL] [Abstract][Full Text] [Related]
39. c-myc and c-myb oncoproteins during induced maturation of human myeloid and erythroid leukaemic lines.
Bains MA; Pedrazzoli P; Hoy TG; Jacobs A
Haematol Blood Transfus; 1989; 32():343-6. PubMed ID: 2696685
[No Abstract] [Full Text] [Related]
40. Inhibition by interleukin 4 of leukemia inhibitory factor-, interleukin 6-, and dexamethasone-induced differentiation of mouse myeloid leukemia cells: role of c-myc and junB proto-oncogenes.
Kasukabe T; Okabe-Kado J; Hozumi M; Honma Y
Cancer Res; 1994 Jan; 54(2):592-7. PubMed ID: 8275499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
